Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309674065> ?p ?o ?g. }
- W4309674065 endingPage "107" @default.
- W4309674065 startingPage "93" @default.
- W4309674065 abstract "This study aimed to evaluate the long-term cost-effectiveness of once-weekly subcutaneous semaglutide versus polyethylene glycol loxenatide (PEG-loxenatide) in patients with type 2 diabetes uncontrolled on metformin, from a Chinese healthcare systems perspective.The study applied the Swedish Institute of Health Economics Diabetes Cohort Model to evaluate the long-term clinical and economic outcomes of once-weekly treatment of semaglutide at 0.5 mg and 1.0 mg, respectively, versus PEG-loxenatide 0.2 mg, over a 40-year time horizon. Baseline cohort characteristics were collected from the SUSTAIN China trial. A network meta-analysis was conducted to obtain comparative treatment effects of once-weekly semaglutide and PEG-loxenatide based on two phase 3a clinical trials. Drug costs were sourced from the national bidding price of China. Outcomes were discounted at 5.0% per annum. One-way sensitivity analysis and probabilistic sensitivity analysis were conducted to assess the uncertainty of the base-case results.When compared with PEG-loxenatide 0.2 mg, the projections of outcomes over the 40-year time horizon in patients with type 2 diabetes uncontrolled on metformin showed that treatment with once-weekly semaglutide 0.5 mg and 1.0 mg were associated with improved discounted life expectancy by 0.08 and 0.12 years, and improved discounted quality-adjusted life expectancy by 0.16 and 0.22 quality-adjusted life-years, respectively. Once-weekly semaglutide 0.5 mg and 1.0 mg were achieved at lifetime cost savings of 19,309 China Yuan (CNY) and 10,179 CNY, respectively. Sensitivity analyses verified the robustness of the results.From the perspective of Chinese healthcare systems, treatment with once-weekly subcutaneous semaglutide represents a dominant option versus PEG-loxenatide for patients with type 2 diabetes uncontrolled on metformin." @default.
- W4309674065 created "2022-11-29" @default.
- W4309674065 creator A5011674603 @default.
- W4309674065 creator A5012578672 @default.
- W4309674065 creator A5020147975 @default.
- W4309674065 creator A5022646934 @default.
- W4309674065 creator A5025302533 @default.
- W4309674065 creator A5045398749 @default.
- W4309674065 creator A5047593836 @default.
- W4309674065 creator A5066494030 @default.
- W4309674065 creator A5069235822 @default.
- W4309674065 creator A5080727885 @default.
- W4309674065 date "2022-11-22" @default.
- W4309674065 modified "2023-10-11" @default.
- W4309674065 title "Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China" @default.
- W4309674065 cites W1526927233 @default.
- W4309674065 cites W1894221112 @default.
- W4309674065 cites W1969335462 @default.
- W4309674065 cites W1994361436 @default.
- W4309674065 cites W2003442297 @default.
- W4309674065 cites W2007057458 @default.
- W4309674065 cites W2009224225 @default.
- W4309674065 cites W2017869783 @default.
- W4309674065 cites W2019950898 @default.
- W4309674065 cites W2054088567 @default.
- W4309674065 cites W2081276121 @default.
- W4309674065 cites W2089770071 @default.
- W4309674065 cites W2091237544 @default.
- W4309674065 cites W2111824270 @default.
- W4309674065 cites W2126252058 @default.
- W4309674065 cites W2131649684 @default.
- W4309674065 cites W2145216999 @default.
- W4309674065 cites W2148946045 @default.
- W4309674065 cites W2162140339 @default.
- W4309674065 cites W2171294019 @default.
- W4309674065 cites W2197271376 @default.
- W4309674065 cites W2425644022 @default.
- W4309674065 cites W2519510391 @default.
- W4309674065 cites W2572398654 @default.
- W4309674065 cites W2602700371 @default.
- W4309674065 cites W2604469807 @default.
- W4309674065 cites W2763071190 @default.
- W4309674065 cites W2766166596 @default.
- W4309674065 cites W2774157762 @default.
- W4309674065 cites W2787255324 @default.
- W4309674065 cites W2801715295 @default.
- W4309674065 cites W2894746763 @default.
- W4309674065 cites W2898542079 @default.
- W4309674065 cites W2900201893 @default.
- W4309674065 cites W2918407168 @default.
- W4309674065 cites W2933306415 @default.
- W4309674065 cites W2945819271 @default.
- W4309674065 cites W2948612418 @default.
- W4309674065 cites W2948976558 @default.
- W4309674065 cites W2971019572 @default.
- W4309674065 cites W2971839927 @default.
- W4309674065 cites W2973758715 @default.
- W4309674065 cites W2974008202 @default.
- W4309674065 cites W2979241049 @default.
- W4309674065 cites W2981016494 @default.
- W4309674065 cites W3020528808 @default.
- W4309674065 cites W3088811300 @default.
- W4309674065 cites W3093123473 @default.
- W4309674065 cites W3111172371 @default.
- W4309674065 cites W3148962211 @default.
- W4309674065 cites W3195404919 @default.
- W4309674065 cites W4200230313 @default.
- W4309674065 cites W4206608028 @default.
- W4309674065 cites W4236501586 @default.
- W4309674065 cites W4290708133 @default.
- W4309674065 doi "https://doi.org/10.1007/s13300-022-01336-7" @default.
- W4309674065 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36414806" @default.
- W4309674065 hasPublicationYear "2022" @default.
- W4309674065 type Work @default.
- W4309674065 citedByCount "1" @default.
- W4309674065 countsByYear W43096740652023 @default.
- W4309674065 crossrefType "journal-article" @default.
- W4309674065 hasAuthorship W4309674065A5011674603 @default.
- W4309674065 hasAuthorship W4309674065A5012578672 @default.
- W4309674065 hasAuthorship W4309674065A5020147975 @default.
- W4309674065 hasAuthorship W4309674065A5022646934 @default.
- W4309674065 hasAuthorship W4309674065A5025302533 @default.
- W4309674065 hasAuthorship W4309674065A5045398749 @default.
- W4309674065 hasAuthorship W4309674065A5047593836 @default.
- W4309674065 hasAuthorship W4309674065A5066494030 @default.
- W4309674065 hasAuthorship W4309674065A5069235822 @default.
- W4309674065 hasAuthorship W4309674065A5080727885 @default.
- W4309674065 hasBestOaLocation W43096740651 @default.
- W4309674065 hasConcept C112930515 @default.
- W4309674065 hasConcept C126322002 @default.
- W4309674065 hasConcept C134018914 @default.
- W4309674065 hasConcept C2777180221 @default.
- W4309674065 hasConcept C2779306644 @default.
- W4309674065 hasConcept C2780323712 @default.
- W4309674065 hasConcept C2781308992 @default.
- W4309674065 hasConcept C2909862629 @default.
- W4309674065 hasConcept C3019080777 @default.
- W4309674065 hasConcept C515549039 @default.